ImmVira completed the first administration of Phase II of MVR-T3011 (intratumoral injection) in the United States and China

Shenzhen, China, June 11, 2021 /PRNewswire/– ImmVira announced that in its phase II clinical trial of its leading oncolytic virus product MVR-T3011* for intratumoral administration (MVR-T3011 IT), ImmVira has completed the first administration of these two drugs medicine China And the United States in May 28 2021 and June 11 2021, respectively.

MVR-T3011 is ImmVira’s proprietary next-generation transgenic oncolytic herpes simplex virus (“oHSV”), which is developed on a new viral backbone design driven by ImmVira’s innovative insights on oncolytic viruses and superior gene recombination technology. The incorporation of two foreign genes, PD-1 antibody and IL-12, further enhanced the immune response. MVR-T3011 is the first pipeline of ImmVira’s ongoing clinical trials, including intratumoral administration of MVR-T3011. Phase I clinical trials started at China in April 2020 And start at United States with Australia in September 2020The data collected from these preliminary phase I clinical studies show good safety and promising efficacy. No dose limiting toxicity was observed in the participants.

The US Phase IIa portion of the study consists of two parts: (i) MVR-T3011 as a single drug for melanoma and metastatic solid tumors; (ii) MVR-T3011 combined with pembrolizumab in the treatment of non-small cell lung cancer. The China Phase IIa (MVR-T3011 as a single drug) study targets head and neck cancer, sarcoma and breast cancer. These multi-center studies cover various indications and provide efficient and cost-effective clinical development strategies to rapidly advance the clinical development of MVR-T3011 across regions.

“Using the OvPENS new drug development platform, ImmVira is a pioneer in this field,” Dr. Zhou Enlai, Chairman of the Board of ImmVira. “ImmVira will make full use of its long-term experience and creative insights in oncolytic viruses to build a broader product pipeline and provide effective, innovative and safe single drugs and combined oncolytic virus therapies for the anti-tumor market.” Professor Bernard Rozman Has resigned as chairman of the board of directors February 2020 Due to personal health reasons, he has not held any positions in ImmVira and its subsidiaries since then. Dr. Zhou Enlai Since being appointed as chairman of the board of directors February 2020.

*Note: MVR-T3011 is the pipeline code representing T3011, the product code registered in the United States and China Used in clinical trials.

View original content and download multimedia:http://www.prnewswire.com/news-releases/immvira-completed-the-first-dosing-for-phase-ii-of-mvr-t3011-intratumoral-injection-in-the-us-and-china- 301311199.html

SOURCE ImmVira